CEO Executive AssistantPain management is one of the most operationally and ethically complex areas in pharmaceutical business. A pharma CEO leading a pain portfolio must navigate opioid risk management obligations, a shifting regulatory landscape, intense public and political scrutiny, the strategic urgency of building a non-opioid pipeline, and the fundamental commitment to ensuring that patients with legitimate pain conditions can access effective therapy. This guide addresses each of these dimensions with operational specificity.
The Pain Management Market: Context for Leadership
Chronic pain affects an estimated 50 million adults in the United States, making it one of the most prevalent conditions in medicine. Yet the opioid epidemic has fundamentally reshaped prescribing behavior, regulatory expectations, and market dynamics in ways that every pharma CEO in this space must understand.
Opioid prescriptions have declined dramatically over the past decade in response to FDA-mandated risk programs, state prescribing limits, CDC guidelines, and payer restrictions. This creates a paradox: millions of patients with legitimate chronic pain have reduced access to opioid therapy, while the illicit fentanyl market has driven most of the ongoing overdose crisis.
For a pharma CEO, this landscape creates both operational obligations and strategic opportunities. The obligations center on robust risk management and compliance. The opportunities lie in developing and commercializing non-opioid and multimodal pain therapies that can serve patients without the regulatory and reputational burden of opioid scheduling.
Opioid Risk Management Operations
Any pharma company with an opioid product in its portfolio operates under specific FDA requirements through the Risk Evaluation and Mitigation Strategy (REMS) program. Managing REMS compliance is a core business operations function, not a peripheral compliance activity.
REMS program administration for extended-release and long-acting (ER/LA) opioids requires patient enrollment, prescriber certification, pharmacy certification, and medication guides distribution. The Opioid Analgesic REMS requires that prescribers complete accredited education, that pharmacies are certified, and that patients receive counseling materials. CEOs must ensure that their REMS program infrastructure is adequately staffed and that audit-ready documentation is maintained continuously.
Pharmacovigilance and safety reporting obligations are heightened for opioid products. Adverse event reporting timelines, signal detection, and periodic safety update reports must meet FDA standards. CEOs should ensure that the pharmacovigilance function has the resources and independence to operate effectively.
Diversion investigation and response is a unique operational requirement for Schedule II controlled substances. When prescribing patterns suggest diversion or when law enforcement contacts the company regarding a prescriber, the response protocol must be clear, documented, and executed consistently. Failure to respond appropriately to diversion signals can result in DEA action.
Litigation management is an ongoing operational reality for opioid manufacturers. CEOs must work closely with general counsel to manage active litigation, monitor the settlement landscape, and ensure that document retention and privilege protocols are maintained.
DEA Compliance: The Non-Negotiable Foundation
Operating in the controlled substance space requires a level of DEA compliance infrastructure that goes far beyond standard pharmaceutical compliance. The DEA registers manufacturers, distributors, and dispensers of controlled substances and has broad authority to investigate, sanction, and revoke registrations.
DEA quota management is a unique feature of controlled substance manufacturing. The DEA sets annual aggregate production quotas (APQ) for each controlled substance, and individual manufacturers receive allocated quotas. CEOs must ensure that procurement, manufacturing planning, and commercial forecasting are aligned with quota realities, and that the regulatory affairs team maintains an active dialogue with DEA to secure adequate quota allocations.
Suspicious order monitoring (SOM) systems are required for distributors and are increasingly expected of manufacturers. An effective SOM system monitors order patterns for anomalies that could indicate diversion, flags suspicious orders for review, and maintains documentation of all decisions. The DEA’s enforcement actions against distributors for SOM failures have been a major driver of the opioid litigation wave, making this an area where CEOs must demand operational excellence.
Manufacturing site security for Schedule II controlled substance production must meet DEA physical security requirements, including vault storage, inventory controls, and employee screening. Regular internal audits of manufacturing site compliance reduce the risk of DEA inspection findings.
Employee training and culture around controlled substance compliance must be embedded throughout the organization, not just in the compliance function. Sales representatives must understand what they can and cannot say about opioid products, and marketing materials must meet FDA promotional standards for controlled substances.
For a comprehensive framework on pharma regulatory operations, see regulatory compliance ops.
Non-Opioid Pipeline Strategy
The strategic imperative for pain portfolio CEOs is clear: the long-term sustainability of the business depends on building a competitive non-opioid pain management pipeline. The market for non-opioid chronic pain therapies is large, underserved, and growing.
Mechanism diversity should guide pipeline investment decisions. Promising non-opioid mechanisms include sodium channel blockers (Nav1.7, Nav1.8), nerve growth factor (NGF) inhibitors, CGRP pathway modulation for headache disorders, neuromodulation devices, and cannabinoid-based therapies where regulatory pathways are clear. CEOs should assess each mechanism against the criteria of clinical differentiation, regulatory pathway clarity, and commercial fit.
Clinical development strategy for non-opioid pain products faces the challenge of clinical trial design in a patient population with high placebo response rates and diverse pain etiologies. Enrichment strategies, adaptive trial designs, and biomarker-driven patient selection can all improve the probability of regulatory success. CEOs should ensure that clinical leadership has specific expertise in pain trial methodology.
Regulatory pathway planning for non-opioid pain products benefits from early FDA engagement through pre-IND meetings and Type B meetings. FDA has signaled support for non-opioid pain innovation through programs such as the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) partnership.
Business development in the non-opioid pain space is active. Biotech companies, academic spinouts, and device companies are all advancing novel approaches. CEOs should ensure that the business development function is scanning this landscape actively and that the organization has the capabilities to evaluate, negotiate, and integrate non-opioid assets.
Patient Access Programs: Balancing Access and Compliance
Pain patients, particularly those with chronic conditions, face significant barriers to accessing effective therapy. High insurance copayments, prior authorization requirements, and pharmacy availability limitations all reduce appropriate access. Patient access programs are both a commercial tool and an ethical obligation.
Copay assistance programs for commercial payers reduce the out-of-pocket burden for insured patients and improve adherence. However, copay assistance for opioid products requires careful program design to ensure compliance with anti-kickback statutes and to avoid creating incentives for inappropriate use.
Prior authorization support services help prescribers navigate the increasingly onerous prior authorization process for pain medications. Staff who specialize in working with payer prior authorization teams, submitting appeals, and navigating peer-to-peer review processes can dramatically reduce the time from prescribing to dispensing.
Specialty pharmacy relationships are important for pain products that require special dispensing conditions, including controlled substance verification and patient counseling. Building strong relationships with specialty pharmacies ensures that patients receive appropriate onboarding and support.
Patient advocacy engagement with pain patient advocacy organizations is an important dimension of market access strategy. Organizations representing chronic pain patients, fibromyalgia patients, and headache disorder patients provide market research, policy advocacy support, and community access to patient populations that are often difficult to reach through traditional channels.
For frameworks on pharmaceutical market access, see pricing and market access ops.
Payer Strategy for Pain Products
The payer environment for pain management products is restrictive and requires sophisticated navigation. Commercial payers, pharmacy benefit managers (PBMs), and government payers have all implemented controls on opioid prescribing that affect non-opioid products as well.
Formulary positioning for non-opioid pain products faces a different competitive landscape than opioids. The primary competition may be generic products, over-the-counter therapies, or non-pharmacological approaches. CEOs must ensure that the market access team builds a formulary strategy grounded in clinical differentiation and health economic evidence.
Step therapy challenges are common for newer, higher-cost non-opioid pain products. Payers frequently require patients to fail generic alternatives before approving branded therapy. Combating step therapy requires both policy engagement and robust medical exception documentation to support prescribers navigating the appeals process.
Medicare and Medicaid considerations are significant given the demographics of chronic pain patients. Part D formulary placement and Medicaid preferred drug list positioning require dedicated engagement with CMS and state Medicaid agencies. CEOs should ensure that government affairs and market access teams are coordinating on these pathways.
Value-based contracts with payers, where pricing is linked to real-world outcomes, are increasingly attractive for non-opioid pain products with strong clinical evidence. Designing and executing these contracts requires data infrastructure, actuarial modeling, and legal expertise. The upfront investment can pay off in preferred formulary placement and reduced rebate burden.
Prescriber Engagement in Pain Medicine
The pain prescriber landscape is complex and has changed significantly in the opioid restriction era. Primary care physicians, pain specialists, anesthesiologists, neurologists, orthopedic surgeons, and oncologists all prescribe pain medications, each with different needs and decision frameworks.
Pain specialist engagement requires deep clinical expertise from field representatives and MSLs. Pain specialists are highly trained clinicians who expect scientifically substantive conversations about mechanism of action, clinical trial data, and patient selection. Field force training in pain science must go well beyond product monograph summaries.
Primary care engagement focuses on appropriate patient identification and adherence support. Primary care physicians manage the bulk of chronic pain patients and are often the gatekeepers for specialty referral. Operational support for prior authorization navigation and patient copay assistance is particularly valued by this audience.
Key account management at health system pain clinics, academic medical centers with pain programs, and integrated delivery networks can drive significant prescription volume. These accounts require relationship management at the organizational level, not just individual prescriber outreach.
Continuing medical education (CME) in pain medicine, developed and delivered through accredited medical education providers, supports prescriber education without the promotional constraints of branded promotion. CEOs should ensure that the medical affairs team has an active CME strategy that addresses unmet educational needs in pain management.
According to the New England Journal of Medicine, the development of non-opioid analgesics that can provide effective pain relief without addiction risk represents one of the most important unmet needs in modern medicine, creating both scientific and commercial urgency for pipeline investment.
Manufacturing and Supply Chain for Controlled Substances
Manufacturing and supply chain operations for controlled substance pain products carry regulatory obligations that significantly increase operational complexity and cost.
DEA Schedule II manufacturing requires vault-level storage, continuous inventory accountability, and strict chain-of-custody documentation from raw material through finished product. Manufacturing site audits by the DEA are a routine reality, and inspection-readiness must be maintained continuously.
Contract manufacturing organization (CMO) management for controlled substances requires selection of CMOs with existing DEA registrations, proven controlled substance handling protocols, and audit history. The due diligence process for controlled substance CMOs is more extensive than for standard pharmaceutical manufacturers.
Cold chain management for certain pain biologics and injectable products adds another layer of supply chain complexity. Temperature excursion monitoring, cold chain qualification, and distribution partner management for temperature-sensitive products must meet both FDA and DEA requirements.
Inventory management and quota alignment requires close coordination between commercial forecasting, manufacturing planning, and regulatory affairs. Undershooting demand because of inadequate quota creates patient access gaps. Overshooting quota allocations is not possible under DEA regulations. The balancing act requires sophisticated forecasting and ongoing DEA quota management.
Financial Discipline and Portfolio Returns
Pain management portfolios carry unique financial characteristics driven by the opioid regulatory environment, litigation costs, and the investment required to build a non-opioid pipeline.
Gross-to-net complexity for pain products includes not just standard payer rebates but also litigation reserves, REMS program costs, and compliance infrastructure investments. CEOs should ensure that financial modeling captures the full cost structure of operating in the controlled substance space.
Litigation reserve management requires close collaboration between finance, legal, and external counsel. Opioid-related litigation is a long-tail financial obligation for companies with historical opioid products. Transparent reserve accounting and proactive settlement management are essential for investor relations and financial stability.
Portfolio ROI assessment should weigh non-opioid pipeline assets on both their commercial potential and their strategic value in diversifying away from controlled substance risk. Pipeline investments in non-opioid mechanisms may be justified at lower expected returns than traditional pharma hurdle rates, given the risk reduction they provide.
Pain management portfolio leadership demands operational rigor, regulatory mastery, and a genuine commitment to serving patients responsibly. CEOs who build compliance cultures, invest in non-opioid innovation, and execute patient access programs with integrity will build sustainable businesses in one of medicine’s most challenging therapeutic areas.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.